• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Anti-Aging
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

The Weekly Roundup: February 26-March 1


ICYMI, this week we had news about late-breaking phase 2 data on rilzabrutinib for CSU, data from the BRAVE-AA1 and BRAVE-AA2 trials for alopecia areata, Rare Disease Day insights, and more.

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.

Despite Maternal Mental Health and Child Atopic Disease Association, This Link Is Not Attributable to Child Mental Health Disorders

Maternal mental health conditions are associated with the majority of atopic diseases, according to a study.

ICYMI: FDA Approves Third Interchangeable Humira Biosimilar Simlandi

Simlandi (adalimumab-ryvk) joins Pfizer’s Abrilada (adalimumab-afzb) and Boehringer Ingelheim’s Cyltezo (adalimumab-adbm) as an interchangeable Humira biosimilar.

Can Costs and Benefits of Psoriasis Treatments Be Better Aligned?

Biologics to treat psoriasis can cost between $1664 and $79,277 a year in the United States, one study found, and these prices are not commensurate with clinical benefits.

Platelet-Rich Plasma for Hair Restoration and Skin Rejuvenation: Benefits Recognized, Consensus Needed

Platelet-rich plasma (PRP) holds great promise for regenerative hair and skin applications, but trials, standards, and protocols are needed, one review has found.

Rilzabrutinib Rapidly Reduces Itch Severity in Adults with Chronic Spontaneous Urticaria

Late-breaking phase 2 data was presented at the 2024 American Academy of Allergy, Asthma and Immunology Annual Meeting.

Hair and Skin Publications From Sub-Saharan Africa Are Steadily Increasing, Researchers Report

Researchers involved in the review said this increase may help lead to more patient education and more tailored products for patients from this region.

Expert Insights Into the Relationship Between the Hippo Pathway and Extensive Fibrosis in HS

Researchers from the University of Michigan and Almirall found that the profibrotic fibroblast response in HS can be modulated through inhibition of the Hippo pathway.

Are Aerobics or Weights Better for Aging Skin?

Resistance training rejuvenates aging skin differently than aerobics training, according to a new study.

Integrated Data From BRAVE-AA1 and BRAVE-AA2 Trials Supports Efficacy of Baricitinib Over 104 Weeks in Alopecia Areata

Long-term treatment showed increased efficacy in patients who responded partially in week 52, indicating the importance of extended therapy for maximizing benefits in certain individuals.

More Research Needed Regarding Dietary Considerations for Patients With Hidradenitis Suppurativa, Review Finds

Findings regarding an association between HS severity and dietary elements such as vitamin D, B12 supplementation, and more, are inconclusive.

Severity of Psoriatic Disease Significantly Associated With Risk of Inflammatory Bowel Disease

A recent study identified an association between psoriasis severity and IBD, Crohn's disease, and ulcerative colitis.

New Topical Agent for Alopecia to Enter Phase 2 Trials

Data on the phase 1 trial of the small molecule agent for treatment of androgenetic alopecia and other forms of hair loss will be presented at the AAD meeting in March.

Surveying Our Readers: What Are Your Thoughts on the New AAD Acne Guidelines?

We want to hear from you. Please take the time to respond to our survey.

Adewole (Ade) Adamson, MD, MPP: Systemic Racism, Patient Access, and Advancing Health Equity

Dermatology Times is recapping our top expert interviews from the month of February.

B-Raf Inhibitor Receives FDA Orphan Drug Designation for Treatment of EGFRI-Induced Acneiform Rash

Most patients undergoing EGFRI treatment for cancer will develop acneiform lesions, yet no drug is currently approved by the FDA for their prevention or treatment.

Delivering on Diversity in Clinical Trials: Getting Started

Susan Taylor, MD, believes in training more investigators that serve diverse populations to enhance clinical trials. Here are a few resources to get started in clinical trials.

Early Intervention: Shutting Down AD’s Atopic March

Timely systemic treatment of atopic dermatitis—before visible lesions appear—may help halt the atopic march into allergies and asthma.

Celebrating Black History Month in Dermatology

Review Dermatology Times’ February content uplifting Black voices.

Revolutionizing GPP Recognition Through Data Collection

This Rare Disease Day, Stefan Weiss, MD, MBA, FAAD, of OM1, shares his expertise in AI’s capabilities in dermatology.

In Japan, Arcutis and Sato Enter Strategic Collaboration and Licensing Agreement for Topical Roflumilast

The collaboration with Sato marks a continued effort of Arcutis to collaborate with pharmaceutical companies and license topical roflumilast in Asia.

Navigating Rare Dermatologic Diseases Using Artificial Intelligence

This Rare Disease Day, Joseph Zabinski, PhD, MEM, of OM1, discusses the role of artificial intelligence in helping to detect rare dermatologic diseases.

Mindera Health and Liviniti Partner to Improve the Management of Psoriasis With Precision Medicine

Mindera Health and Liviniti Partner to Improve the Management of Psoriasis With Precision Medicine

Rare Disease Rundown: Rare Disease News From the Past 365 Days

Today is Rare Disease Day. Here's a look back at news related to rare skin conditions over the past year.

POLL: Which of These Rare Dermatologic Diseases Have You Encountered in Your Practice?

Click here to answer our poll on rare dermatologic diseases.

Dermatology Times February 2024 Recap

Dermatology Times is looking back on the top stories in dermatology from the month of February.

Discovering Dermatology Times: February

Learn more about the in-depth topics covered in the February 2024 print issue of Dermatology Times.

Dermatology Conferences and Meetings Calendar 2024: March

Dermatology Times asked our readers to share what conferences they are looking forward to in the first quarter of 2024.

Johnson & Johnson Innovative Medicine Sponsorship Expands GW Teledermatology Program

The EACH one TEACH one program aims to enhance access to dermatologic care for residents of southeast Washington, DC, Wards 7 and 8.

Suicide Risk in Isotretinoin Users: New Data

Despite its black box warning, isotretinoin does not appear to increase the risk of suicide in acne patients, a finding investigators say is reassuring in their latest research.

Drug Combination May Benefit Patients with Transplanted Kidneys, Advanced Skin Cancers

In most kidney transplant recipients with advanced skin cancer, 2 checkpoint inhibitors are needed to boost the immune system, according to a new study.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.